News Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
2.71 ^USD	-2.17%		-7.82%	+59.41%

Mar. 21	Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	CI
Mar. 13	Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City	Apr. 11	PR
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	Mar. 28	PR
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	Mar. 21	CI
Heron Therapeutics : Q4 2023 Earnings Call Presentation	Mar. 14	PU
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	Mar. 13	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Mar. 13	MT
Heron Therapeutics Shares Soar After Q4 Results Beat	Mar. 13	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating	Mar. 13	MT
Heron Therapeutics : Q4 2023 Earnings Call Presentation	Mar. 12	PU
Heron Therapeutics: Q4 Earnings Snapshot	Mar. 12	AQ
Transcript : Heron Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M	Mar. 12	MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates	Mar. 12	PR
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	Mar. 12	CI
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024	Feb. 28	PR
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef	Jan. 24	DJ
Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	Jan. 24	AQ
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	Jan. 24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Summary

Filters